GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shijiazhuang Yiling Pharmaceutical Co Ltd (SZSE:002603) » Definitions » EBIT

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) EBIT : ¥639 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shijiazhuang Yiling Pharmaceutical Co EBIT?

Shijiazhuang Yiling Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥378 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥639 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shijiazhuang Yiling Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2024 was 10.10%. Shijiazhuang Yiling Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 17.28%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shijiazhuang Yiling Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 2.15%.


Shijiazhuang Yiling Pharmaceutical Co EBIT Historical Data

The historical data trend for Shijiazhuang Yiling Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shijiazhuang Yiling Pharmaceutical Co EBIT Chart

Shijiazhuang Yiling Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 707.96 1,422.88 1,559.61 2,809.78 1,723.11

Shijiazhuang Yiling Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,462.23 486.96 182.77 -408.85 378.01

Competitive Comparison of Shijiazhuang Yiling Pharmaceutical Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Shijiazhuang Yiling Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shijiazhuang Yiling Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shijiazhuang Yiling Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shijiazhuang Yiling Pharmaceutical Co's EV-to-EBIT falls into.



Shijiazhuang Yiling Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥639 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shijiazhuang Yiling Pharmaceutical Co  (SZSE:002603) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shijiazhuang Yiling Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=1552.232 * ( 1 - 18.06% )/( (12492.058 + 12693.808)/ 2 )
=1271.8989008/12592.933
=10.10 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=16979.327 - 3340.788 - ( 1146.481 - max(0, 4446.701 - 6543.746+1146.481))
=12492.058

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=17128.471 - 3131.5 - ( 1303.163 - max(0, 4285.574 - 6656.361+1303.163))
=12693.808

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Shijiazhuang Yiling Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1512.036/( ( (7305.662 + max(1556.939, 0)) + (7318.455 + max(1319.253, 0)) )/ 2 )
=1512.036/( ( 8862.601 + 8637.708 )/ 2 )
=1512.036/8750.1545
=17.28 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2401.186 + 2458.692 + 336.797) - (3340.788 + 0 + 298.948)
=1556.939

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2563.254 + 2000.817 + 237.341) - (3131.5 + 0 + 350.659)
=1319.253

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shijiazhuang Yiling Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=638.893/29768.831
=2.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shijiazhuang Yiling Pharmaceutical Co EBIT Related Terms

Thank you for viewing the detailed overview of Shijiazhuang Yiling Pharmaceutical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Business Description

Traded in Other Exchanges
N/A
Address
No. 7 Tianfu street, Biology and medicine industrial base, Huangcun town, Daxing district, Beijing, CHN
Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company engages in the pharmaceutical manufacturing. The company is principally engaged in the research, development, manufacturing, and sales of traditional Chinese pharmaceutical products, especially in the fields of cardiovascular and cerebrovascular diseases, respiratory diseases, tumor, diabetes and related complications. Its products include innovative drug series, chemical drugs, Chinese medicine series, and health products.
Executives
Zhang Qiu Lian Directors, executives
Han Yue Zhi Executives
Zhao Shao Hua Executives
Wang Wei Executives
Gao Xue Dong Supervisors
Wu Yi Ling Director
Gao Xiu Qiang Executives
Wu Xiang Jun Directors, executives
Guo Shuang Geng Director
Wang Hua Securities Affairs Representative
Dai Feng Xiang Directors, executives
Liu Gen Wu Supervisors
Wang Wei Ping Directors, executives
Xu Wei Dong Director
Wu Rui Directors, executives

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Headlines

No Headlines